Distinctive nicotinic acetylcholine receptor functional phenotypes of rat ventral tegmental area dopaminergic neurons

Kechun Yang^{1,3}, Jun Hu¹, Linda Lucero², Qiang Liu¹, Chao Zheng¹, Xuechu Zhen³, Guozhang Jin³, Ronald J. Lukas² and Jie Wu¹

Divisions of ¹ Neurology and ² Neurobiology, Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, AZ 85013-4496, USA 3 Department of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

Dopaminergic (DAergic) neuronal activity in the ventral tegmental area (VTA) is thought to contribute generally to pleasure, reward, and drug reinforcement and has been implicated in nicotine dependence. nAChRs expressed in the VTA exhibit diverse subunit compositions, but the functional and pharmacological properties are largely unknown. Here, using patch-clamp recordings in single DAergic neurons freshly dissociated from rat VTA, we clarified three functional subtypes of nAChRs (termed ID, IID and IIID receptors) based on whole-cell current kinetics and pharmacology. Kinetic analysis demonstrated that comparing to ID, IID receptor-mediated current had faster activation and decay constant and IIID receptor-mediated current had larger current density. Pharmacologically, ID receptor-mediated current was sensitive to the *α***4***β***2-nAChR agonist RJR-2403 and antagonist dihydro-***β***-erythroidine (DH***β***E); IID receptor-mediated current was sensitive to the selective** *α***7-nAChR agonist choline and antagonist methyllycaconitine (MLA); while IIID receptor-mediated current was sensitive to the** *β***4-containing nAChR agonist cytisine and antagonist mecamylamine (MEC). The agonist concentration–response relationships demonstrated that IID receptor-mediated current exhibited the highest EC⁵⁰ value compared to ID and IIID receptors, suggesting a relatively low agonist affinity of type IID receptors. These results suggest that the type ID, IID and IIID nAChR-mediated currents are predominately mediated by activation of** *α***4***β***2-nAChR,** *α***7-nAChR and a novel nAChR subtype(s), respectively. Collectively, these findings indicate that the VTA DAergic neurons express diversity and multiplicity of functional nAChR subtypes. Interestingly, each DAergic neuron predominantly expresses only one particularly functional nAChR subtype, which may have distinct but important roles in regulation of VTA DA neuronal function, DA transmission and nicotine dependence.**

(Received 3 September 2008; accepted after revision 20 November 2008; first published online 1 December 2008) **Corresponding author** J. Wu: Division of Neurology, Barrow Neurological Institute, 350 West Thomas Road, Phoenix, AZ 85013-4496, USA. Email: jie.wu@chw.edu

Brain reward systems are essential for adaptation and survival, but their activation by exogenous agents can produce drug dependence (White, 2002). Although mechanisms involved in drug dependence are not fully defined, the mesocorticolimbic dopaminergic (DAergic) system, and the ventral tegmental area (VTA) in particular, appear to play major roles (Nisell*et al.* 1994; Pontieri*et al.* 1996; Spanagel & Weiss, 1999; Dani & De Biasi, 2001; Dani *et al.* 2001). For example, increases in dopamine (DA) release from VTA DAergic neurons onto their targets have been implicated in drug reinforcement (Spanagel & Weiss, 1999).

Studies linking nicotine dependence to VTA DAergic neurons, DA and nicotinic acetylcholine receptors (nAChRs) include indications that nicotine self-administration is significantly reduced after lesioning of midbrain DAergic neurons or injection of a nAChR antagonist into the VTA (Corrigall *et al.* 1994; Sziraki *et al.* 2002). Electrophysiological studies using brain slices showed that modulation of pre- or postsynaptic nAChRs altered DAergic neuronal activity and/or DA release in the

This paper has online supplemental material.

VTA or substantia nigra pars compacta (SNc) through apparently complex mechanisms (Pidoplichko *et al.* 1997; Wonnacott *et al.* 2000; Klink *et al.* 2001; Mansvelder *et al.* 2003; Wooltorton *et al.* 2003; Pidoplichko *et al.* 2004). nAChR subunits are diversely expressed in the VTA (Wada *et al.* 1989; Le Novere *et al.* 1996; Charpantier *et al.* 1998; Zoli *et al.* 1998; Klink *et al.* 2001; Azam *et al.* 2002; Le Novere *et al.* 2002), thus positioning nAChRs to contribute to biologically rewarding events, but also to nicotine dependence (Dani & Heinemann, 1996).

Studies using wild-type and specific nAChR subunit knockout mice have suggested that two possible heteromeric nAChR subunit combinations in midbrain DAergic neurons are α 4 α 5 α 6(β 2)₂ and α 4 α 5(β 2)₂, whereas homomeric α 7-nAChRs are expressed on less than one-half of VTA DAergic neurons (Klink *et al.* 2001). Other studies suggest that functional *α*6*β*2 (or *α*4*α*6*β*2)-nAChRs are mainly located at DAergic neuronal terminals (Champtiaux *et al.* 2003) and that *α*4*β*2-nAChRs represent the majority of functional, heteromeric nAChRs on DAergic neuronal soma (Champtiaux *et al.* 2003). nAChRs that contain the *β*2 subunit appear to be essential for nicotine reinforcement and self-administration, which are prerequisites for nicotine dependence (Picciotto *et al.* 1998; Mameli-Engvall *et al.* 2006). In mice lacking the nAChR *α*4 subunit, there is no nicotine-induced increase of DA release in the striatum (Marubio *et al.* 2003), although functional nAChRs remain on DAergic neurons (Picciotto *et al.* 1998). Moreover, nicotine-induced reward, tolerance and sensitization are enhanced in mice engineered to express gain-of-function *α*4∗-nAChR (Tapper *et al.* 2004). However, our understanding of functional nAChR subtype expression in the VTA and the pharmacological properties remains incomplete, in part due to limitations in brain slice preparations in analysis of the kinetics of nAChR-mediated whole-cell currents and pharmacology (Pidoplichko *et al.* 1997; Klink *et al.* 2001; Mansvelder *et al.* 2003; Wooltorton *et al.* 2003). On the other hand, the use of neurons in primary culture allows for faster drug application and washout and has provided fundamental information about functional nAChRs in hippocampal neurons (Alkondon & Albuquerque, 1993), but with limited ability to determine neuronal phenotype and degree of maturation. Another difficulty when studying nAChRs is that their expression, function and pharmacology are altered during the first postnatal month in rodents (Azam *et al.* 2007).

To complement previous approaches and to deal with some of these confounds, we chose to use freshly dissociated, single neurons from the VTA of rats of known age in preparations allowing for determination of neuronal phenotype using electrophysiological and cytochemical approaches. We also used patch-clamp whole-cell current recording techniques that allow for rapid drug application and washout (using a computer-controlled U-tube drug application system) and exploited the ability to minimize space-clamp problems during recording. Based on work focusing on characterization of functional nAChR subtypes, we have identified three functional subtypes of nAChRs naturally expressed on the VTA DAergic neurons, and we provide evidence that while there are multiple functional subtypes of nAChRs on VTA DAergic neurons, each DAergic neuron predominantly expresses only one, a ID, IID or IIID receptor.

Methods

Single DAergic neuron dissociation

The protocol for the preparation of single neurons from the rat VTA was approved by the Institutional Animal Care and Use Committee of the Barrow Neurological Institute.

Single neurons were acutely dissociated from the VTA of 2–3-week-old Wistar rats following procedures previously described (Wu *et al.* 2004). Briefly, rats were anaesthetized with isoflurane, and brain tissue was rapidly removed and immersed in cold (2–4◦C) dissection solution that contained (in mm): 136.7 NaCl, 5 KCl, 0.1 Na₂HPO₄, 0.2 KH₂PO₄, 9.84 Hepes, 16.6 D-glucose and 21.9 sucrose; pH 7.3; 330 mosmol l⁻¹; oxygenated with 100% O₂ (Ishihara *et al.* 1995). From each rodent, two $400 \mu m$ coronal slices containing the VTA were cut using a vibratome (Vibratome 1000 Plus, St Louis, MO, USA). After cutting, the slices were continuously bubbled with 95% O_2 –5% CO_2 at room temperature $(22 \pm 1°C)$ for at least 1 h in artificial cerebrospinal fluid (ACSF), which contained (in mM): 124 NaCl, 5 KCl, 24 NaHCO₃, 1.3 MgSO₄, 1.2 KH₂PO₄, 2.4 CaCl₂ and 10 glucose; pH 7.4. Thereafter, the slices were treated with pronase (1 mg per 6 ml) at 31◦C for 30 min in ACSF. After enzyme treatment, the slices were washed twice with well-oxygenated ACSF. The VTA was first identified using a stereomicroscope and then micropunched out from the slices using a well-polished needle (0.6 mm diameter). Each punched piece was then separately transferred to a 35 mm culture dish filled with well-oxygenated standard extracellular solution, which contained (in mM): 150 NaCl, 5 KCl, 1 $MgCl₂$, 2 CaCl₂, 10 glucose and 10 Hepes; pH 7.4 (with Tris-base). Each punched piece was then dissociated mechanically using a fire-polished micro-Pasteur pipette under an inverted microscope (Olympus IX-70, Lake Success, NY, USA). The separated cells adhered to the bottom of the culture dish within 30 min. We used only VTA neurons that maintained their original morphological features of polygonal, large- or medium-sized somata with two to four thick, primary dendritic processes.

Rat nAChR subunit	Sense primer $(5' \rightarrow 3')$	Antisense primer $(5' \rightarrow 3')$
α ₂	CTTCTGAGATGATCTGGATCC	GAGGTGACAGCAGAATCTCGCTAG
α ₃	CATGTCTCAGCTGGTGAAG	GCCGGCGGGATCCAAGTCACTTC
α 4	GAATGTCACCTCCATCCGCATC	CCGGCA(A/G)TTGTC(C/T)TTGACCAC
α 5	GGGTTCG(T/C)CCTGTGGAACACCTGA	GGTCCTCTAG(A/G)ATTATATCAACCTG
α 6	TGTTCCAGCAGATAACATCTG	CTACCTCCTT(G/T)GTTTCATTGTGGCT
α .	GTTCTATGAGTGCTGCAAAGAGCC	CTCCACACTGGCCAGGCTGCAG
α 9	GCTCAGAAATTGTTCAGCGATC	CAGCAGGCATGCCATGGACC
β 2	CTCCAACTCAATGGCGCTGTTCAG	CCATGAGCGAAACTTCATGGTGCAA
β 3	GGTTCCATCAGAATCGCTC	CCGTGAGAAAAGACAACCCCAGG
β 4	CAAGAGTGCCTGCAAGATTGAGGTG	GGAGCTGACTGCAGACTTAGGAGC
GAPDH	CGGATTTGGCCGTATCGGACGCC	GCCTTGGCAGCACCAGTGGATGC

Table 1. Primers used for initial amplification and Southern hybridization analysis of VTA nAChR subunit expression

Perforated patch-clamp whole-cell recordings

Perforated-patch whole-cell recording techniques were employed (Wu *et al.* 2004). Compared to performing conventional whole-cell recordings, this approach was crucial for obtaining stable nicotinic responses from dissociated VTA neurons, presumably due to minimal perturbation of the intracellular environment. Pipettes $(3-5 M\Omega)$ used for perforated-patch recordings were filled with intracellular recording solution, which contained (in mM): 140 potassium gluconate, 10 KCl, 5 $MgCl₂$ and 10 Hepes; pH 7.2 (with Tris-OH) freshly supplemented before use with amphotericin B to 200 μ g ml⁻¹ from a 40 mg ml−¹ DMSO stock. The liquid-junction potential was −14 mV (calculated using Clampex 9.2, Axon Instruments, Union City, CA, USA), and corrections were made for junction potentials *post hoc*. After tight seal (> 2 G Ω) formation, about 5–20 min was required for conversion to the perforated-patch mode, and an access resistance of $< 60 \text{ M}\Omega$ was accepted to start the experiments. Series resistance was not compensated in this study. Data were acquired at 10 kHz, filtered at 2 kHz, digitized on-line (Digidata 1322 series A/D board, Axon Instruments), and displayed and stored on a PC computer. Rapid application of drugs was performed using a computer-controlled 'U-tube' system (Wu *et al.* 2004) that allowed for complete exchange of solution surrounding the recorded cell within 30 ms. Periods of drug exposure are specified in the text and figures or legends. When ACh was used as a nicotinic agonist, 1μ M atropine was routinely added to exclude actions mediated via endogenous muscarinic receptors, and this manipulation is known to have no clear effect on ACh-induced currents (Wu *et al.* 2004). All experiments were performed at room temperature. To enable identification of single, dissociated VTA neurons, cells were labelled with a fluorescent dye (lucifer yellow; Sigma-Aldrich, St Louis, MO, USA; 1.0 mg ml−¹ in the recording electrode) in

some experiments. After conversion from perforated to conventional whole-cell recording mode, the dye was injected into the cytoplasm by a pulse (200 ms, 0.5 Hz) of hyperpolarizing current (1.0 nA) for 3 min. Labelled cells were visualized using epifluorescence microscopy.

Immunocytochemical staining

Dissociated VTA neurons were fixed with 4% paraformaldehyde for 15 min, rinsed three times with phosphate-buffered saline (PBS), and treated with saponin (1 mg ml−1, Sigma-Aldrich) for 5 min as a permeabilizing agent. After rinsing four times with PBS, the neurons were incubated at room temperature in anti-tyrosine hydroxylase (TH) primary antibody (AB152; Chemicon International, Temecula, CA, USA) diluted 1 : 1000 in Hanks' balanced salt solution (supplemented with 5% bovine serum albumin as a blocking agent) for 30 min. Following another three rinses with PBS, a secondary antibody (cy3-conjugated, anti-mouse IgG; Sigma-Aldrich) was applied at room temperature for 30 min (diluted 1 : 100). After rinsing a final three times with PBS, the labelled cells were visualized using fluorescence microscopy.

nAChR subunit mRNA detection

RT-PCR assays followed by Southern hybridization with nested oligonucleotides were done as previously described to identify nAChR subunit transcripts and to quantify levels of expression normalized both to housekeeping gene expression and levels of expression in whole brain (Zhao *et al.* 2003; Wu *et al.* 2004), but using primers designed to detect rat nAChR subunits (see Table 1). The Southern hybridization technique coupled with quantification using electronic isotope counting (Instant Imager, Canaberra Instruments, Meridien, CT, USA)

yielded results equivalent to those obtained using real-time PCR analysis.

Chemicals and statistics

The drugs used in the present study were (–)nicotine, ACh, choline, cytisine, methyllycaconitine (MLA),

Figure 1. RT-PCR analysis of nAChR subunit mRNA levels expressed in the rat VTA

RT-PCR products in the VTA (*A*) or in the whole brain (*B*) from postnatal 14–21-day-old Wistar rats and corresponding to the indicated nAChR subunits or to the housekeeping gene GAPDH were resolved on an agarose gel calibrated by the flanking 100 bp ladders (heavy band is 500 bp) and visualized using ethidium staining. Note that the representative gel shown for whole brain did not contain a sample for the nAChR α 3 subunit RT-PCR product, which typically is similar in intensity to the sample on the gel for the VTA. *C*, results of RT-PCR amplification followed by Southern hybridization with ³²P-labelled, nested oligonucleotides were quantitatively compared after normalization to the GAPDH internal control and to levels of each specific mRNA in whole rat brain (ordinate: $+$ s.E.M.) for the indicated. Note that it is not possible to compare the level of expression of one subunit as message to another's based on the approach used.

mecamylamine (MEC), dihydro-*β*-erythroidine (DH*β*E), DA (all purchased from Sigma-Aldrich), and RJR-2403 (purchased from Tocris Bioscience, Ellisville, MO, USA). The *α*-conotoxin MII was a gift obtained from Dr J. Michael McIntosh. Concentration–response relationships for nicotinic ligand action on nAChR-mediated whole cell currents were normalized, averaged, and fitted to the Hill equation to derive both EC_{50} and Hill coefficient values. All results are presented as mean ± S.E.M. Student's *t* test was used to compare two groups of data, and significance was set at *P <* 0.05.

Results

Naturally expressed nAChR subunits in the rat VTA

Diverse expression of nAChR subunits by VTA neurons might have important functional consequences related to nicotine dependence. RT-PCR analysis was done to identify expressed nAChR subunits in micropunched VTA samples from Wistar rats like those processed for electrophysiological studies as described below. Data were analysed to quantify nAChR subunit mRNA levels from the VTA compared to levels of expression across whole brain. Expression of nAChR *α*3–*α*7 and *β*2–*β*4 subunits, but not *α*2 or *α*9 subunits, was evident in the VTA (Fig. 1*A*), whereas whole-brain samples showed the richest expression of nAChR *α*2, *α*4, *α*5, *α*7 and *β*2–*β*3 subunits (Fig. 1*B*; note that the *α*3 subunit product was not applied to this representative, ethidium-stained gel). RT-PCR followed by Southern hybridization using ³²P-labelled, nested oligonucleotide probes was used to give real-time PCR-quality quantification of nAChR subunit message levels in the VTA. When expressed as a factor of whole-brain expression for all data normalized to mRNA encoding glyceraldehyde phosphate dehydrogenase (GAPDH) as a control for the amount of input mRNA, the data indicated that VTA levels of expression of nAChR *α*3, *α*4, *α*5 and *β*4 subunits were comparable to those in whole brain, whereas levels of *α*7 and *β*2 subunits were enriched ∼3.5-fold in the VTA (Fig. 1*C*). There was a ∼6-fold enrichment of nAChR *β*3 subunit message in the VTA (Fig. 1*C*), and nAChR *α*6 subunit message levels were *>* 20-fold higher in the VTA (Fig. 1*C*). The VTA contains both DAergic and GABAergic neurons, which could contribute to the diversity in nAChR subunit expression. However, the complex pattern of nAChR subunit expression as mRNA (*α*3–*α*7, *β*2–*β*4) in the rat VTA is consistent with both previous observations (Wada *et al.* 1989; Azam *et al.* 2002) and findings from patch-clamp recordings combined with single-cell RT-PCR studies using mouse midbrain slices (Klink *et al.* 2001).

Identification of VTA DAergic neurons

We desired to evaluate nAChR function on single DAergic neurons freshly dissociated from the rat VTA (Fig. 2*Ab–d*), which required that we first defined the region of interest and the cells contained within it. The VTA was identified in coronal slicesmade through themidbrainwith reference to the SN, and TH immunostaining patterns of sister samples were used to verify selection of the micropunched VTA (Fig. 2*Aa*). Under perforated-patch recording conditions, the average resting potential for dissociated VTA neurons was -41.8 ± 1.4 mV (before a correction for junction potential, $n = 52$). Junction potentials for potassium gluconate electrodes used are about −14 mV as estimated using pCLAMP 9.2. Identification of DAergic neurons was confirmed early in the recording session based on: (1) 0.5–3.2 Hz $(1.77 \pm 0.14 \text{ Hz}, n = 52)$ spontaneous action potential firing with each action potential having a long duration (3.84 \pm 0.18 ms decay to 50% of peak amplitude, $n = 52$, Fig. 2*Ba*), (2) inhibition of spontaneous firing during exposure to $10 \mu M$ DA in all recorded neurons represented either as a complete block of action potentials (Fig. 2*Ba*) or as significantly reduced neuronal firing, and (3) expression of a hyperpolarization-induced current (H-current; voltage-clamp mode, Fig. 2*Bb*). The peak current at -120 mV was -73.4 ± 10.1 pA, $n = 21$; Fig. 2*Bc*). Retrospective confirmation of the DAergic phenotype was accomplished by labelling the recorded neuron (Fig. 2*Ca*) with a fluorescent dye (lucifer yellow, 1 mg ml⁻¹; injected at the end of the recording session after conversion from perforated to conventional

Figure 2. Identification of VTA DAergic neurons

A, TH immunostaining of a slice containing the VTA region revealing DAergic neurons (small black cells, *a*) clustered below the SN. Phase contrast images of acutely dissociated, single neurons from the rat VTA in reference to a 50 μ m calibration bar (*b–d*). *B*, patch-clamp recording under current-clamp mode of an acutely dissociated, VTA DAergic neuron showing characteristic spontaneous action potential firing at ∼3 Hz with a long (> 2.5 ms) spike duration (see inset and 3 ms calibration bar) and sensitivity to 10 μ M DA (horizontal bar denotes period of application; *a*) and hyperpolarization-induced current (H-current in voltage-clamp mode (*b*)), and a summary of current amplitude of H-current from 21 neurons tested (*c*). *C*, images (left to right) of an acutely dissociated single neuron from the VTA examined after recording under phase contrast microscopy (left), identified by injection with lucifer yellow (middle), and subjected to TH immunostaining (right; scale bar = 50 μ m).

whole-cell recording configuration) followed by microscopic visualization of the stained neuron based on both lucifer yellow fluorescence (Fig. 2*Cb*) and a positive immunocytochemical reaction for TH (Fig. 2*Cc*). Whereas electrophysiological properties were used to identify all VTA DAergic neurons studied in this work, anti-TH immunostaining was only conducted on a subset of recorded neurons, but TH-positive staining always correlated with electrophysiological features in all 11 neurons tested.We realize that there are indications that H-current-positive neurons may not always be DAergic (Margolis *et al.* 2006), but we are confident that the collective properties of the cells identified in this study as DAergic reliably allowed us to make those identifications. We also identified VTA non-DAergic neurons in the course of these studies based on electrophysiological properties (supplementary Fig. 1). However, because we were not able to confirm a GABAergic phenotype of these non-DAergic neurons through systematic studies employing immunohistochemistry (i.e. GAD67 staining), we focused on DAergic but not GABAergic neurons in the present study.

ACh-induced whole-cell currents in VTA DAergic neurons

We characterized functional nAChR subtypes expressed on VTA DAergic neurons because of their potential relevance in mediating nicotine dependence. To accomplish this, we performed perforated patch-clamp recordings using single DAergic neurons freshly dissociated from the rat VTA (from 117 rats, a total of 188 neurons responded to ACh). Response kinetics allowed for classification, at least operationally, of three types of nAChR subtypes based on their functional nAChR phenotypes (Fig. 3). Type ID receptor-mediated currents showed rapid activation of a peak inward current and moderate and incomplete decay during agonist challenge from peak to steady-state current levels with

A, under voltage-clamp at a holding potential of −45 mV, 1 mM ACh applied for 2 s induced whole-cell currents in VTA DAergic neurons. Whole-cell currents were classified based on response amplitudes and kinetics as type ID responses displaying modest peak but more robust steady-state responses, type IID responses displaying large peak but low steady-state responses, or type IIID responses displaying large peak components that were only slowly inactivating (left to right: 50, 100 and 200 pA current amplitude calibration bars; 2 s time calibration bar; period of drug application denoted by horizontal bars). Traces shown were recorded from different VTA DAergic neurons and are representative of those obtained from neurons of the same class (see other representative traces in the following figures). *B*, features of ACh-induced whole-cell responses (ordinates: + S.E.M.; peak amplitude, pA, *a*; steady-state amplitude, pA, *b*; net charge, fC, *c*) for the identified type ID (filled bars, *n* = 32), IID (open bars, $n = 11$) or IIID receptor-mediated currents (cross-hatched bars, $n = 8$). The whole-cell current decay constant is shown in *Bd*, in which type ID (*n* = 9) and IID (*n* = 23) receptor-mediated whole-cell currents exhibited two phases (tau fast: τ ^f and tau slow: τ s), while type IIID (*n* = 8) responses exhibited only one decay phase. ∗∗*P* < 0.01.

						τ (ms)		
Type	n	Age (days)	$R_{\rm t}$ (ms)	Peak (pA)	Steady state (pA)	Fast	Slow	
ID	32	$17 + 1$	$64 + 8$	$75 + 8$	22 ± 3	700 ± 162 (n = 9)	$4040 \pm 1833 (n=9)$	
IID		$16 + 1$	$41 + 7$	$107 + 19$	$13 + 5$	56 \pm 8 (n = 23)**	200 ± 46 (n = 23) ^{**}	
IIID		$16 + 1$	$101 + 22^{\#}$	$658 + 154***$	$283 \pm 85***$		505 \pm 87	

Table 2. Features of whole-cell current responses evoked by 1 mM ACh in VTA DAergic neuronal classes

Whole-cell current responses of acutely dissociated VTA DAergic neurons segregated into three classes, types ID, IID and IIID as described in the text, were analysed (numbers of neurons tested, *n*; age of animals used to isolate neurons, age) to yield mean ± S.E.M. for the parameters indicated (*R*t, rising time: time to peak current, ms; peak: peak current amplitude, pA; steady-state: steady-state current amplitude, pA; *τ*: e-fold current decay time, ms). ∗∗*P <* 0.01 compared to ID. #*P <* 0.05 compared between IID and IIID; ##*P <* 0.01 compared between IID and IIID.

steady-state currents being $28.7 \pm 2.3\%$ ($n = 32$) of peak values (Fig. 3*A*, left). Type IID receptor-mediated currents exhibited fast activation and rapid, more complete decay to steady-state levels that were $10.5 \pm 3.4\%$ (*n* = 11) of peak current values (Fig. 3*A*, middle). Whole-cell current profiles of type IIID receptors exhibited slow activation and inactivation and typically had larger peak and steady-state current amplitudes (the ratio of steady-state/peak was $41.3 \pm 4.4\%$; $n = 8$) than responses mediated by type ID or IID receptors (Fig. 3*A*, right). The values for current rising time (10–90% of peak response) for type ID, IID or IIID receptors were 87.6 ± 7.3 $(n=20), 45.2 \pm 3.3$ $(n=20),$ or 144.8 ± 15.6 ms $(n=20),$ respectively. Analyses showed statistically significant differences in rising time for ID *versus* IID responses (*P <* 0.001), ID *versus* IIID responses (*P <* 0.01), and IID *versus* IIID responses (*P <* 0.001). To validate impressions formed based on whole-cell current traces (Fig. 3*A*), statistical analyses indicated larger peak amplitudes, steady-state amplitudes and total current net charge for responses mediated by type IIID receptors to 1 mM ACh (Fig. 3*Ba–c*). Steady-state/peak current ratios and net charge were higher for type ID than for type IID receptor-mediated currents (Fig. 3*Bb–c*). The whole-cell current decay constant showed two phases for ID and IID, and statistical analyses indicated that both tau-fast (τ_f) and tau-slow (τ_s) were larger for ID than that for IID receptor-mediated currents. There was only one phase of current decay for IIID responses (Fig. 3*Bd*). Table 2 summarizes kinetic analyses of these three different kinds of ACh-inducedwhole-cell currentsfrom 51 recordedVTA DAergic neurons.

Responses to nicotinic agonists

In order to further define functional nAChR profiles of VTA DAergic neurons, agonist sensitivity profiles were determined. Type ID receptors were strongly activated by the *α*4*β*2-nAChR-selective agonist RJR-2403 (0.1 mM; Papke *et al.* 2000), weakly by the *α*7-nAChR-selective agonist choline (10 mM; although sometimes there was

elicitation of a quickly inactivating peak current), but not by cytisine (50 *μ*M; cytisine is a weak, partial agonist at *α*4*β*2-nAChR but is much more efficacious at *α*3*β*4- or *α*4*β*4-nAChR) (Fig. 4*A* and *D*). These findings suggest that *α*4*β*2-nAChR is the dominant, functional nAChR subtype to mediate type ID responses. Type IID receptors were strongly activated by the *α*7-nAChR-selective agonist choline (which elicited virtually no steady-state current response), weakly by RJR-2403 (and then predominantly of a steady-state response), but not by cytisine, suggesting that *α*7-nAChR is the functionally predominant nAChR to mediate type IID responses (Figs 4*B* and *D*). Type IIID responses to ACh or nicotine were large and decayed slowly. These cells responded weakly to RJR-2403, were insensitive to choline, but exhibited greater responsiveness to cytisine compared to type ID or IID receptor-mediated currents (Fig. 4*C* and *D*). This profile suggests that the predominant, functional nAChR subtype(s) of type IIID responses is neither *α*4*β*2- nor *α*7-nAChR, but must be one or more nAChRs of different subunit composition. Classification of 188 ACh-responsive VTA DAergic neurons (from 117 rats) based on nAChR agonist sensitivity indicated that 46% were type ID, 46% were type IID, and 8% were type IIID nAChR-mediated responses (Fig. 4*E*).

Agonist concentration dependence of VTA DAergic nAChRs

Concentration–response profiles (Fig. 5*A*–*C*) were obtained for agonists other than ACh showing highest efficacy in eliciting responses from different VTA DAergic neuronal types (Figs $4E$ and 5). EC_{50} values (and 95% confidence intervals) for peak currents and Hill coefficients (\pm s.e.m.), respectively, were 12 μ M (8.5–16.0) and 0.9 ± 0.1 for RJR-2403 for type ID receptor-mediated currents ($n = 6$; Fig. 5A and *D*); 4.6 mm (3.5–5.9) and 0.9 ± 0.1 for type IID responses induced by choline ($n = 5$; Fig. 5*B* and *D*), and 5.1 μ M (1.9–13.0) and 0.7 \pm 0.2 for type IIID responses to nicotine ($n = 4$; Fig. 5*C* and *D*).

These results indicate that pharmacological profiling of acutely dissociated DAergic neurons from the rat VTA underscores their classification, at least operationally, and provides further insight into the predominance of nAChR subtypes expressed on VTA DAergic neurons. To further characterize type ID, IID and IIID receptor subtypes, we also derived concentration–response relationships for type ID, IID and IIID responses to nicotine (Fig. 6). Nicotine at 100μ M induced three types of whole-cell current responses (Fig. 6*A*). Based on concentration–response curves, nicotine EC_{50} values (and 95% confidence intervals) for peak current responses and Hill coefficients were 12.6 $μ$ M (11.8–13.4) and $1.3 ± 0.04$ for type ID responses $(n=9)$, 35.4 μ M (17.5–71.6) and 0.8 ± 0.1 for type IID responses ($n = 10$), and 6.2 μ M $(2.5-15.5)$ and 0.7 ± 0.1 for type IIID responses $(n=5)$. Studies also were done using nAChR subtype-selective antagonists, which were applied for 2 min to cells prior to continued application during a 2 s challenge with nicotine. Nicotine concentration–response profiles were obtained for type ID receptor-mediated currents in the absence or presence of the *α*7-nAChR-selective antagonist, MLA (10 nM; Fig. 6*C*) or for type IID receptor-mediated currents in the absence or presence of the *α*4*β*2-nAChR-selective antagonist, DH*β*E (1 *μ*M; Fig. $6D$). EC_{50} values and Hill coefficients for peak current of type ID responses to nicotine were 7.5 *μ*M and 1.0 in the absence of MLA compared to 12.1μ M and 0.6 in the presence of MLA ($n = 3$). EC₅₀ values and Hill coefficients for type IID responses to nicotine were 43.2 μ M and 0.7 in the absence of DH*β*E and 60.2 μ M and 1.6 in the presence of DH β E ($n = 5$). The shift to lower apparent potency and a larger Hill slope for type IID responses in the presence of DH*β*E is consistent with

Whole-cell current responses to the indicated agonists (ACh, choline, RJR-2403, cytisine and nicotine at the indicated concentrations; left to right; period of drug application denoted by bar; 2 s time and 100 or 200 pA current amplitude calibration bars) for type ID (*A*), IID (*B*), or IIID receptor-mediated currents (*C*). Traces in each row (ID, IID or IIID) were recorded from the same neuron. *D*, efficacies of the indicated agonists at the concentrations shown in *A–C* in eliciting peak whole-cell currents (ordinate: normalized to the peak current response in the presence of 1 mM ACh; indicated as a horizontal dashed line) for type ID (filled bars), type IID (open bars) or type IIID (cross-hatched bars) responses averaged (+ S.E.M.) from 6 to 8 neurons tested. *E*, percentages of VTA DAergic neuronal responses from 188 VTA dissociated neurons tested.

sharpening of the nicotine response more toward one dominated by a lower-affinity, *α*7-nAChR. It is less clear why the type ID response changes as it does in the absence or presence of MLA. However, most important are the observations that MLA predominantly reduces peak and not steady-state components in type ID responses and has modest effects, and that DH*β*E has modest effects on type IID receptor-mediated currents that include reductions in peak and steady-state components. Thus, these data are consistent with dominance of *α*4*β*2-nAChR-mediated currents for type ID responses and of *α*7-nAChR-mediated currents for type IID responses.

Antagonist inhibition of VTA DAergic neuronal responses to ACh

Sensitivity to functional blockade of VTA DAergic neuronal responses to 1 mm ACh was assessed using antagonists thought to be relatively selective for specific nAChR subtypes. MLA at 1 nM (2 min pretreatment followed by application of antagonist during agonist exposure) selectively blocked the rapidly activated, initial component of ACh-induced current but not the steady-state component of type ID (Fig. 7*A*) and IID (Fig. 7*B*) responses, and it did not block any element of type IIID responses (Fig. 7*C*). DH*β*E at 1 *μ*M (2 min pretreatment followed by application of antagonist during agonist exposure) inhibited the steady-state component of ACh-induced type ID (Fig. 7*A*) and IID responses (Fig. 7*B*), but it less robustly inhibited type IIID neuronal responses (Fig. 7*C*). Effects of DH*β*E on peak currents were less robust although evident for type IID more than for type IIID and least for type ID responses (Fig. 7*B* and *C*). Sensitivity to $100 \mu M$ MEC (coapplied with agonist) was evident for responses from each nAChR subtype-mediated currents (Fig. 7*A*–*C*), and the steady-state components of type ID (Fig. 7*A*) and IIID

Typical whole-cell current response traces (see time and current amplitude calibrations bars) were recorded in the presence of the indicated concentration (presented above the horizontal bar denoting the duration of agonist exposure) of RJR-2403 acting at type ID receptors (*A*), choline acting at type IID receptors (*B*), or nicotine acting at type IIID receptors (*C*). *D*, concentration–response curves for the three classes of nAChR (ID, IID, IIID)-mediated currents responding (ordinate: peak current amplitude normalized to that in the presence of 100 $μ$ M nicotine or RJR-2403 or 10 mM choline indicated by $*$; vertical bars: \pm s.E.M.) to the indicated concentration (abscissa: μ M, log scale) of RJR-2403 (type ID responses; ●), choline (type IID responses; \blacktriangle) or nicotine (type IIID responses; \blacksquare) yielded the indicated EC_{50} values and Hill coefficients (see inset and text). These values were determined based on fits of the data to the logistic equation where EC_{50} values are the concentrations of agonists needed to achieve 50% of the calculated maximum response to agonist. Hill coefficients indicated are for fits from zero basal levels to maximum peak current values that are 113%, 153% and 102%, respectively, for ID, IID and IIID responses at the agonist concentration used to normalize the data as described above. Data are from 4 to 6 cells for each class of neuron.

responses (Fig. 7*C*) were most sensitive. Across nAChR subtypes, and at the concentrations used, the steady-state components of type ID responses were sensitive to both DH*β*E and MEC. Type IID receptor-mediated fast responses showed the highest sensitivity to MLA (accounting for the different concentrations used). Type IIID receptor-mediated responses were most sensitive to MEC. Interestingly, none of the nicotinic responses of acutely dissociated VTA DAergic neurons were blocked by 100 nM *α*-conotoxin MII, an *α*6/*α*3-nAChR subtype-selective antagonist (supplementary Fig. 2*A*) as has been demonstrated in other studies that used different preparations (Klink *et al.* 2001). However, using the same concentration of *α*-conotoxin MII, we found that this compound inhibited GABAergic, spontaneous inhibitory postsynaptic currents in DAergic neurons mechanically dissociated from rat VTA and apparently appose to GABAergic boutons (supplementary Fig. 2*B*). Sensitivity to nAChR antagonists also supports whole-cell current kinetic analyses and nAChR agonist sensitivity studies (Table 3) in discriminating three subtypes of functional nAChRs on VTA DAergic neurons. The collective results from antagonist profiling suggest that type ID and type IID responses are predominantly mediated by activities of *α*4*β*2- and *α*7-nAChRs, respectively, whereas type IIID receptor subtype seems to express a different, dominant nAChR subtype(s) insensitive to MLA and only weakly sensitive to DH*β*E.

Antagonist concentration dependence for inhibition of functional nAChRs

To lend further insight into the nAChR subtypes that are expressed on VTA DAergic neurons, perforated whole-cell current responses were obtained in the presence of 1 mM ACh coapplied with different concentrations of antagonists (no pretreatment). Since naturally expressed nAChR subtypes are expressed in the same VTA DAergic neuron, 1 mm ACh activated all possible nAChR subtypes. As shown in Fig. 7, the steady-state component of responses mediated by type ID and

Figure 6. Concentration–response relationships for actions of nicotine on ID, IID and IIID receptors *A*, typical traces of nicotine-induced currents via ID, IID and IIID receptors. *B*, responses of type ID (\blacktriangle), IID (\blacksquare) or IIID (\bullet) receptors (ordinate: peak current amplitude normalized to that in the presence of 1000 μ M nicotine indicated by *; mean values \pm s.E.M.) to the indicated concentration (abscissa: μ M, log scale) of nicotine. See text for EC₅₀ values and Hill coefficients. *C*–*D*, comparison of nicotine-induced currents mediated by type ID receptors with or without MLA (*C*) or by type IID receptors with or without DHβE (*D*). For these experiments, whole-cell current responses were determined at different concentrations of nicotine and then again in the presence of nicotine and the indicated antagonists after a 2 min pretreatment with the antagonist, all using the same cell.

P* < 0.05 compared to *I*_{ACh}, ^{}*P* < 0.01 compared to *I*_{ACh}.

IID receptors likely reflected *α*4*β*2-nAChR-mediated currents while the sharp component of peak current mostly reflected *α*7-nAChR-mediated current. Thus, we analysed antagonist concentration-dependent inhibition by measuring current area for type ID responses but peak current for type IID responses. When evaluating current response area, IC_{50} values (and 95% confidence intervals) and Hill coefficients $(\pm s.E.M.)$, respectively, for type ID responses were 5.3 μ M (4.6–6.1) and 0.9 ± 0.1 (*n* = 6) for DH*β*E and 908.6 nM (647.7–1275.0) and 0.9 ± 0.1 ($n = 6$) for MEC. IC₅₀ values (and 95%) confidence intervals) and Hill coefficients $(\pm s.E.M.)$, respectively, for peak current of type IID responses were 61.7 μ M (39.4–93.4) and 0.7 \pm 0.1 for DH β E (*n* = 6) and 21 μ M (15.6–28.1) and 0.9 \pm 0.1 for MEC (*n* = 6). IC_{50} values (and 95% confidence intervals) and Hill coefficients $(\pm s.E.M.)$, respectively, for peak current of type IIID responses were $> 100 \mu M$ for DH β E (*n* = 3)

and $0.9 \mu M$ (0.2–4.8) and 0.7 ± 0.2 for MEC ($n = 5$, Fig. 8). Interestingly, IC₅₀ values were ∼10-fold lower for DH*β*E and MEC when the effects were assessed on integrated whole-cell current (area) instead of peak current amplitude of type ID and type IID responses or for MEC actions at type IIID receptors (where the effects of DH*β*E were always weak), reflecting higher sensitivity to block of steady-state current components. For type ID and type IID receptor-mediated currents, this also could reflect lower sensitivity of quickly activating and inactivating responses mediated by *α*7-nAChR to either antagonist relative to more sustained responses characteristic of *α*4*β*2-nAChR. Overall, DH*β*E had weak effects and MEC had the strongest effects on type IIID nAChR-mediated responses.

Relatively selective *α*7-nAChR antagonists such as *α*-bungarotoxin (*α*-BGT) and MLA are popular tools used in the nAChR field. The slow onset of functional

Figure 7. Antagonist sensitivity of VTA DAergic neuronal responses

A, representative whole-cell current traces are shown for responses to (left to right; agonist exposure periods are shown by the horizontal bars, and antagonist pre/coexposure duration is shown by the open/back slash bars) 1 mm ACh alone, ACh during and after 2 min of pre-exposure to 1 nm MLA or to 1 μ m DH β E, ACh during exposure to 100 μ M MEC, or ACh exposure after antagonist washout for type ID or IID responses (50 pA current amplitude calibration bar) or type IIID responses (300 pA current amplitude calibration bar); 2 s time calibration bar. $V_{\rm H} = -45$ mV.

block mediated by *α*-BGT and the slow recovery from those effects (Wu *et al.* 2004) confounds the obtaining of concentration–inhibition curves using toxin in dissociated neuron with patch-clamp recordings. Thus, and because type IIID responses were insensitive to MLA, we focused on studies using MLA and evaluated its effects on type ID and type IID responses to 1 mM ACh. Co-exposure to MLA during 2s application of 1 mm ACh inhibited a small fraction of the peak current of type ID and IID responses (IC₅₀ = 17 nm, Hill = 0.6, $n = 6$ for ID responses; $IC_{50} = 130 \text{ nm}$, $Hill = 0.7$, $n = 6$ for IID responses; Fig. 9*A*), suggesting that without pretreatment, MLA exhibits relatively low-potency block of naturally expressed *α*7-nAChR. To confirm this notion, studies of type IID receptor-mediated currents subjected to no $(IC_{50} = 400 \text{ nm}, \text{ Hill} = 0.5)$ or 2 min pretreatment $(IC_{50} = 0.35 \text{ nm}, \text{ Hill} = 1.7)$ with MLA indicated that pretreatment markedly (∼1000 fold) increased the ability of MLA to block choline-induced peak (*α*7 type) current responses (Fig. 9*B*, Table 4), which was consistent with previous observations (Wu *et al.* 2004).

Discussion

In the present study, we have identified and characterized three functional subtypes of nAChRs in single DAergic neurons freshly dissociated from rat VTA using patch-clamp recordings combined with nicotinic pharmacological tools. Based on whole-cell current kinetics and pharmacological profiles, ACh induces three types of whole-cell currents, termed ID, IID and IIID type receptor-mediated currents, which are

Figure 8. Concentration–effect relationships for inhibition by DH*β***E or MEC of ACh-induced currents in VTA DAergic neurons**

The effects of nicotinic antagonists at the indicated concentrations (abscissa: log μ M; DH β E effects are shown on the left, panel *A*, and MEC effects are shown on right, panel *B*) on peak current amplitude (peak) or net current during ligand application (integrated charge; area) upon exposure to 1 mm ACh were defined for each class of nAChR subtypes (ID, IID and IIID). DHβE (*A*) or MEC (*B*) were coapplied with ACh. Single neurons were used to obtain data at the entire set of antagonist concentrations. Each symbol was normalized to 1 mm ACh-induced response and represents the average response from 4 to 6 neurons (vertical bars represent S.E.M.).

	n	Peak					Area						
		DH β E (μ M)		MEC (μM)		MLA (nm)		DH β E (μ M)		MEC (μM)		MLA (nm)	
Type		IC_{50}	Hill	IC_{50}	Hill	IC_{50}	Hill	IC_{50}	Hill	IC_{50}	Hill	IC_{50}	Hill
ID	6	28	1.0	1.2	1.1	17	0.6	5.3	0.9	0.9	0.9	8.2	0.4
IID	6	62	0.7	21	0.9	130	0.7	1.2	0.6	0.4	0.6	156	0.5
IIID	4	>100	0.3	0.9	0.7	NE	NE	>100	0.4	0.1	1.2	NE	NE

Table 4. Pharmacological features of nicotinic responses in VTA DAergic neurons – antagonists

Agonist used for these experiments was 1 mm ACh. All antagonists were coapplied with ACh. NE: no effect.

predominantly mediated by *α*4*β*2-nAChR, *α*7-nAChR and a receptor of more complex subuni composition (*β*4 containing), respectively. Interestingly, although most DAergic neurons express multiple functional nAChR subtypes, each DAergic neuron predominantly expresses only one particularly functional nAChR subtype, which may have distinct but important roles in regulation of VTA DA neuronal function, DA transmission, and nicotine dependence.

Diversity in nAChR subunit and subtype expression in VTA DAergic neurons

A large number of nAChR subunits have been found to be expressed in the current and in previous studies in the VTA or more broadly across midbrain DAergic or other brain regions (Wada *et al.* 1989; Le Novere *et al.* 1996; Charpantier *et al.* 1998; Zoli *et al.* 1998; Klink *et al.* 2001; Azam *et al.* 2002; Le Novere *et al.* 2002). This could reflect expression of a large number of nAChR subunits within a single type of cell in a brain region. The present study is consistent with and has extended these previous observations. We have shown that somatodendritic nAChRs are expressed on acutely dissociated DAergic neurons in a diverse manner. Type ID receptor reflects a predominance of *α*4*β*2-nAChR expression, type IID receptor is predominantly *α*7-nAChR, while type IIID receptor is assembled by nAChR subunits other than *α*4*β*2- or *α*7-nAChR.

Instead or in addition, this diversity of functional nAChR subtypes could also reflect an admixture of simpler patterns of subunit expression per specific cell type across several cell types. Indeed, projection or local neurons or different glial cell types, or even subsets of these cell types, could have different, and perhaps simpler, patterns of nAChR subunit expression. This possibility is supported by the current studies, which demonstrate that VTA DAergic neurons can be classified, at least operationally, based on their somatodendritic, functional nAChR phenotypes.

Figure 9. Pharmacological profiles for MLA inhibition of functional nAChR responses in VTA DAergic neurons Type ID or IID responses were induced by 1 mm ACh and type IID responses were induced by 10 mm choline in the presence of the indicated concentration (abscissa: log nM) of MLA coapplied with agonist (no pretreatment) or applied for 2 min prior to and then continuing during agonist exposure (pretreatment). Peak or integrated charge (area) of resultant whole-cell current responses were then determined (ordinates). *A*, comparison of effects of coincubation with MLA on peak current components to 1 mm ACh of type ID and IID responses. *B*, effects of MLA coapplication or pretreatment on 10 mM choline-induced peak current of type IID responses. All symbols represent average responses from 6 to 8 neurons (vertical bars represent \pm s.e.m.).

Pharmacological characterization of VTA DAergic neuronal nAChRs

Classification of functional nAChR subtypes was based mainly on pharmacological profiles in the present study.

In type ID receptor-mediated currents, the EC_{50} value for the relatively selective *α*4*β*2-nAChR full agonist RJR-2403 was 12μ M, which is comparable to that for the agonist acting at human *α*4*β*2-nAChRs heterologously expressed in SH-EP1 cells (Eaton *et al.* 2003). IC₅₀ values (peak current, no pretreatment with antagonist) for the antagonists DH*β*E and MEC were 29 and 10 *μ*M, respectively (Fig. 8*A* and *B*). However, these IC_{50} values are higher than those obtained in studies of their effects on *α*4*β*2-nAChRs heterologously expressed in *Xenopus* oocytes (Chavez-Noriega *et al.* 1997) or HEK 293 cells (Buisson *et al.* 1996). This could reflect real differences in native *versus* heterologously expressed receptors or in technique. For example, Buisson *et al.* (1996) measured the effects of DH*β*E on the steady-state component of nicotinic responses instead of on peak currents, and we found a ∼10-fold difference in IC_{50} values when making those comparisons internally (Fig. 8*A*). Rank order antagonist potency of DH*β*E and MEC is identical and their absolute IC_{50} values are comparable whether acting on steady-state components of type ID responses or on human *α*4*β*2-nAChRs heterologously expressed in SH-EP1 cells (Eaton *et al.* 2003). These findings indicate that type ID receptors have a predominant, functional *α*4*β*2-nAChR phenotype with regard to somatodendritic expression.

In type IID receptor-mediated currents, the EC_{50} value for nicotine was 35.4 *μ*M and for the selective *α*7-nAChR agonist choline was 4.6 mM, which nevertheless is consistent with the reported low agonist affinity of a variety of heterologously or naturally expressed *α*7-nAChRs (Alkondon & Albuquerque, 1993; Zhao *et al.* 2003; Wu *et al.* 2004). In the current and previous (Zhao *et al.* 2003; Wu *et al.* 2004) studies, type IID receptor-mediated current responses were sensitive to low concentrations of either *α*-BGT or MLA when the appropriate pretreatment was applied. Thus, somatodendritic expression of *α*7-nAChRs predominated on type IID receptors.

With regard to type IIID receptors, which seem to be expressed in the VTA but not in the SN (Matsubayashi *et al.* 2004), the sensitivity of their functional nAChRs to cytisine and insensitivity to DH*β*E is consistent with their expression of functional nAChRs containing the *β*4 subunit. Their insensitivity to MLA or choline suggests a lack of *α*7-nAChR, and their level of expression of *α*4*β*2-nAChRs must be low due to low sensitivity to RJR-2403. *α*6∗-nAChRs are among the functional subtypes identified in midbrain neurons (Klink *et al.* 2001), but 100 nM *α*-conotoxin MII failed to inhibit functional responses mediated by all three types (ID, IID, IIID) of receptor-mediated currents (supplementary Fig. 2). These results suggest that under the natural conditions, the functional *α*6∗-nAChRs are expressed on somatodendrite of VTA DAergic neurons at a level that seems to be too low to be detected. However, after genetic enhancement of *α*6∗-nAChR expression, the function of *α*6∗-nAChRs can be clearly tested using the whole-cell recording technique (Drenan *et al.* 2008). Although the subunit makeup of type IIID nAChRs is unknown, the number of possible assembly partners has been narrowed (e.g. at least *β*4-containing nAChRs).

Interestingly, our findings echo the theme developed by Albuquerque and colleagues in their classification of ACh-induced whole-cell currents in rat hippocampal cultures (Alkondon & Albuquerque, 1993) or slices (Albuquerque *et al.* 1997) in that rat VTA type ID and IID responses have features like rat hippocampal type II and type IA responses, respectively. Moreover, functional and pharmacological properties of naturally expressed, type 1, type 2 and type 3 nAChRs categorized based on studies using wild-type or *β*2 subunit knockout mice (Zoli *et al.* 1998) have pharmacological features like the nAChR subtypes that dominate responses of the currently described type IID, type ID or type IIID receptors, respectively. We show a detectable *α*7-nAChR-like component in type ID receptor-mediated current and a small, *α*4*β*2-nAChR-like component in type IID receptor-mediated current, suggesting that there may be a continuum in proportions of expression of these nAChR subtypes across operationally defined type ID and IID receptor classes in the rat VTA.

Our findings about type ID and IID receptors on VTA DAergic neurons are partially consistent with the observations that VTA/SNc DAergic neurons express *α*4*α*6*α*5*β*2-, *α*4*α*5*β*2 (not *α*6)-, and *α*7-nAChRs using midbrain slice preparations from nAChR subunit knockout mice (Klink *et al.* 2001). However, it is more difficult to reconcile previous findings by Klink *et al.* (2001) or by Matsubayashi *et al.* (2004), who studied slices or acutely dissociated neurons from rat SNc, with our findings regarding type IIID receptors in the rat VTA. Perhaps these differences are due to the different species and/or brain regions studied. The nAChRs studied by others might be expressed on more distal dendrites perhaps preserved in slices but not in acutely dissociated neurons. Also, it is possible that some nAChR subtypes might not survive the acute dissociation process. Functional nAChRs containing *α*6 subunits on DAergic neuronal terminals rather than on soma (Champtiaux *et al.* 2003) would have escaped detection in our studies. Moreover, only afew type IIID receptor-mediated currents were identified by us, and a very small component of type IIID responses could be due to *α*7- and/or *α*4*β*2-nAChRs. However, the large amplitude, slowly decaying constant responses showing sensitivity to cytisine

but insensitivity to RJR-2403, choline, or DH*β*E suggest that type IIID receptors assemble with very little if any *α*4*β*2- or *α*7-nAChR. We doubt that inclusion of *α*5 or *β*3 'wild-card' subunits would account for the observed functional profile of type IIID nAChRs composed of *α*4 and *β*2 or *α*7 subunits, and any contribution by *α*6 subunits is difficult to reconcile with *α*-conotoxin MII-insensitivity of responses. Responses to cytisine and low sensitivity to DH*β*E suggest the inclusion in functional nAChRs of *β*4 rather than (or in addition to) *β*2 and *α*7 or *α*4 subunits. *α*3 and *α*6 subunits are candidate subunits along with *β*2, *β*3 and/or *β*4 subunits in type IIID nAChRs although insensitivity of functional responses to *α*-conotoxin MII was observed. There also could be roles for *α*5 or *β*3 subunits in nAChRs expressed in type IIID (or type ID or IID) receptors.

Significance of the existence of multiple functional nAChR subtypes on VTA DAergic neurons

The current finding that there is diversity of functional nAChR expression just on the soma and minimal dendrites of acutely dissociated rat VTA DAergic neurons has many implications and possible interpretations. The VTA is the origin of several DAergic projections including those to the nucleus accumbens and prefrontal cortex. Perhaps the functional nAChR profile for these cells segregates with projection phenotype. A similar argument could be made about DAergic neuronal phenotype as influenced by neuronal inputs. Yet to be defined are how DAergic neuronal functional nAChR phenotypes change with development and ageing and whether or not they are plastic and responsive to environmental inputs and changes in behaviour as occur during initiation and development of drug dependence, especially if type ID and IID receptors actually lie on a continuum of nAChR phenotypes.

The current study demonstrates that the acutely dissociated neuronal preparation is a valuable complement to tissue slice, primary culture, and *in vivo* studies of nicotinic responses potentially relevant to nicotine dependence. We have been able to use this preparation to obtain heretofore unrealized detail in pharmacological characterization of freshly prepared neurons and their somatodendritic nAChRs. Not only do VTA DAergic neurons express multiple nAChR subtypes, but they also can be distinguished based on their functional nAChR phenotypes. Continuing studies of how properties of types ID, IID and IIID receptors respond to acute or chronic exposure to nicotine promises to improve our understanding of the roles of VTA nAChRs in nicotine reinforcement and dependence (Di Matteo *et al.* 2007), in VTA function, and in the control of DAergic signalling.

References

- Albuquerque EX, Alkondon M, Pereira EF, Castro NG, Schrattenholz A, Barbosa CT, Bonfante-Cabarcas R, Aracava Y, Eisenberg HM & Maelicke A (1997). Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. *J Pharmacol Exp Ther* **280**, 1117–1136.
- Alkondon M & Albuquerque EX (1993). Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. I. Pharmacological and functional evidence for distinct structural subtypes. *J Pharmacol Exp Ther* **265**, 1455–1473.
- Azam L, Chen Y & Leslie FM (2007). Developmental regulation of nicotinic acetylcholine receptors within midbrain dopamine neurons. *Neuroscience* **144**, 1347–1360.
- Azam L, Winzer-Serhan UH, Chen Y & Leslie FM (2002). Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons. *J Comp Neurol* **444**, 260–274.
- Buisson B, Gopalakrishnan M, Arneric SP, Sullivan JP & Bertrand D (1996). Human *α*4*β*2 neuronal nicotinic acetylcholine receptor in HEK 293 cells: a patch-clamp study. *J Neurosci* **16**, 7880–7891.
- Champtiaux N, Gotti C, Cordero-Erausquin M, David DJ, Przybylski C, Lena C, Clementi F, Moretti M, Rossi FM, Le Novere N, McIntosh JM, Gardier AM & Changeux JP (2003). Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. *J Neurosci* **23**, 7820–7829.
- Charpantier E, Barneoud P, Moser P, Besnard F & Sgard F (1998). Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area. *Neuroreport* **9**, 3097–3101.
- Chavez-Noriega LE, Crona JH, Washburn MS, Urrutia A, Elliott KJ & Johnson EC (1997). Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h*α*2*β*2, h*α*2*β*4, h*α*3*β*2, h*α*3*β*4, h*α*4*β*2, h*α*4*β*4 and h*α*7 expressed in *Xenopus* oocytes. *J Pharmacol Exp Ther* **280**, 346–356.
- Corrigall WA, Coen KM & Adamson KL (1994). Selfadministered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. *Brain Res* **653**, 278–284.
- Dani JA & De Biasi M (2001). Cellular mechanisms of nicotine addiction. *Pharmacol Biochem Behav* **70**, 439–446.
- Dani JA & Heinemann S (1996). Molecular and cellular aspects of nicotine abuse. *Neuron* **16**, 905–908.
- Dani JA, Ji D & Zhou FM (2001). Synaptic plasticity and nicotine addiction. *Neuron* **31**, 349–352.
- Di Matteo V, Pierucci M, Di Giovanni G, Benigno A & Esposito E (2007). The neurobiological bases for the pharmacotherapy of nicotine addiction. *Curr Pharmacol Des* **13**, 1269–1284.
- Drenan RM, Grady SR, Whiteaker P, McClure-Begley T, McKinney S, Miwa JM, Bupp S, Heintz N, McIntosh JM, Bencherif M, Marks MJ & Lester HA (2008). In vivo activation of midbrain dopamine neurons via sensitized, high-affinity *α*6 nicotinic acetylcholine receptors. *Neuron* **60**, 123–136.

Eaton JB, Peng JH, Schroeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo YP, Steinlein O & Lukas RJ (2003). Characterization of human *α*4*β*2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. *Mol Pharmacol* **64**, 1283–1294.

Ishihara K, Alkondon M, Montes JG & Albuquerque EX (1995). Nicotinic responses in acutely dissociated rat hippocampal neurons and the selective blockade of fast-desensitizing nicotinic currents by lead. *J Pharmacol Exp Ther* **273**, 1471–1482.

Klink R, de Kerchove d'Exaerde A, Zoli M & Changeux JP (2001). Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. *J Neurosci* **21**, 1452–1463.

Le Novere N, Corringer PJ & Changeux JP (2002). The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. *J Neurobiol* **53**, 447–456.

Le Novere N, Zoli M & Changeux JP (1996). Neuronal nicotinic receptor α 6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. *Eur J Neurosci* **8**, 2428–2439.

Mameli-Engvall M, Evrard A, Pons S, Maskos U, Svensson TH, Changeux JP & Faure P (2006). Hierarchical control of dopamine neuron-firing patterns by nicotinic receptors. *Neuron* **50**, 911–921.

Mansvelder HD, De Rover M, McGehee DS & Brussaard AB (2003). Cholinergic modulation of dopaminergic reward areas: upstream and downstream targets of nicotine addiction. *Eur J Pharmacol* **480**, 117–123.

Margolis EB, Lock H, Hjelmstad GO & Fields HL (2006). The ventral tegmental area revisited: is there an electrophysiological marker for dopaminergic neurons? *J Physiol* **577**, 907–924.

Marubio LM, Gardier AM, Durier S, David D, Klink R, Arroyo-Jimenez MM, McIntosh JM, Rossi F, Champtiaux N, Zoli M & Changeux JP (2003). Effects of nicotine in the dopaminergic system of mice lacking the *α*4 subunit of neuronal nicotinic acetylcholine receptors. *Eur J Neurosci* **17**, 1329–1337.

Matsubayashi H, Inoue A, Amano T, Seki T, Nakata Y, Sasa M & Sakai N (2004). Involvement of *α*7- and *α*4*β*2-type postsynaptic nicotinic acetylcholine receptors in nicotine-induced excitation of dopaminergic neurons in the substantia nigra: a patch clamp and single-cell PCR study using acutely dissociated nigral neurons. *Brain Res Mol Brain Res* **129**, 1–7.

Nisell M, Nomikos GG & Svensson TH (1994). Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. *Synapse* **16**, 36–44.

Papke RL, Webster JC, Lippiello PM, Bencherif M & Francis MM (2000). The activation and inhibition of human nicotinic acetylcholine receptor by RJR-2403 indicate a selectivity for the *α*4*β*2 receptor subtype. *J Neurochem* **75**, 204–216.

Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, Fuxe K & Changeux JP (1998). Acetylcholine receptors containing the *β*2 subunit are involved in the reinforcing properties of nicotine. *Nature* **391**, 173–177.

Pidoplichko VI, DeBiasi M, Williams JT & Dani JA (1997). Nicotine activates and desensitizes midbrain dopamine neurons. *Nature* **390**, 401–404.

Pidoplichko VI, Noguchi J, Areola OO, Liang Y, Peterson J, Zhang T & Dani JA (2004). Nicotinic cholinergic synaptic mechanisms in the ventral tegmental area contribute to nicotine addiction. *Learning Memory* **11**, 60–69.

Pontieri FE, Tanda G, Orzi F & Di Chiara G (1996). Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. *Nature* **382**, 255–257.

Spanagel R & Weiss F (1999). The dopamine hypothesis of reward: past and current status. *Trends Neurosci* **22**, 521–527.

Sziraki I, Sershen H, Hashim A & Lajtha A (2002). Receptors in the ventral tegmental area mediating nicotine-induced dopamine release in the nucleus accumbens. *Neurochem Res* **27**, 253–261.

Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, Whiteaker P, Marks MJ, Collins AC & Lester HA (2004). Nicotine activation of *α*4[∗] receptors: sufficient for reward, tolerance, and sensitization. *Science* **306**, 1029–1032.

Wada E, Wada K, Boulter J, Deneris E, Heinemann S, Patrick J & Swanson LW (1989). Distribution of *α* 2, *α* 3, *α* 4, and *β* 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. *J Comp Neurol* **284**, 314–335.

White FJ (2002). A behavioral/systems approach to the neuroscience of drug addiction. *J Neurosci* **22**, 3303–3305.

Wonnacott S, Kaiser S, Mogg A, Soliakov L & Jones IW (2000). Presynaptic nicotinic receptors modulating dopamine release in the rat striatum. *Eur J Pharmacol* **393**, 51–58.

Wooltorton JR, Pidoplichko VI, Broide RS & Dani JA (2003). Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. *J Neurosci* **23**, 3176–3185.

Wu J, George AA, Schroeder KM, Xu L, Marxer-Miller S, Lucero L & Lukas RJ (2004). Electrophysiological, pharmacological, and molecular evidence for *α*7-nicotinic acetylcholine receptors in rat midbrain dopamine neurons. *J Pharmacol Exp Ther* **311**, 80–91.

Zhao L, Kuo YP, George AA, Peng JH, Purandare MS, Schroeder KM, Lukas RJ & Wu J (2003). Functional properties of homomeric, human *α*7-nicotinic acetylcholine receptors heterologously expressed in the SH-EP1 human epithelial cell line. *J Pharmacol Exp Ther* **305**, 1132–1141.

Zoli M, Lena C, Picciotto MR & Changeux JP (1998). Identification of four classes of brain nicotinic receptors using *β*2 mutant mice. *J Neurosci* **18**, 4461–4472.

Acknowledgements

Work toward this project was supported by grants from the Arizona Biomedical Research Commission (0028 and 0057), the Institute for Mental Health Research, and Philip Morris International through their External Research Program, the Barrow Neurological Foundation (Robert and Gloria Wallace Foundation and Marjorie Newsome and Sandra Solheim Aiken funds), and National Institutes of Health grants NS40417 and DA15389. The authors thank Kevin Ellsworth for his assistance in preparing the manuscript.

Supplemental material

Online supplemental material for this paper can be accessed at: http://jp.physoc.org/cgi/content/full/jphysiol.2008.162743/DC1